You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGalantamine
Accession NumberDB00674  (APRD00206, EXPT01628)
TypeSmall Molecule
GroupsApproved
DescriptionA benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer's disease and other central nervous system disorders. [PubChem]
Structure
Thumb
Synonyms
(-)-Galanthamine
Galanthamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-galantamine ERCapsule, extended release16 mgOralAuro Pharma Inc2014-06-12Not applicableCanada
Auro-galantamine ERCapsule, extended release24 mgOralAuro Pharma Inc2014-06-12Not applicableCanada
Auro-galantamine ERCapsule, extended release8 mgOralAuro Pharma Inc2014-06-12Not applicableCanada
Galantamine ERCapsule, extended release16 mgOralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERCapsule, extended release24 mgOralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERCapsule, extended release24 mgOralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERCapsule, extended release8 mgOralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERCapsule, extended release8 mgOralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERCapsule, extended release16 mgOralSanis Health Inc2016-01-11Not applicableCanada
Galantamine HydrobromideCapsule, extended release16 mg/1OralPatriot Pharmaceuticals, LLC2004-12-22Not applicableUs
Galantamine HydrobromideTablet, film coated12 mg/1OralYabao Pharmaceutical Co., Ltd. Beijing2001-03-01Not applicableUs
Galantamine HydrobromideTablet, film coated8 mg/1OralPatriot Pharmaceuticals, LLC2001-02-28Not applicableUs
Galantamine HydrobromideCapsule, extended release24 mg/1OralPatriot Pharmaceuticals, LLC2004-12-22Not applicableUs
Galantamine HydrobromideTablet, film coated12 mg/1OralAvera Mc Kennan Hospital2015-09-02Not applicableUs
Galantamine HydrobromideTablet, film coated12 mg/1OralPatriot Pharmaceuticals, LLC2001-02-28Not applicableUs
Galantamine HydrobromideTablet, film coated4 mg/1OralYabao Pharmaceutical Co., Ltd. Beijing2001-03-01Not applicableUs
Galantamine HydrobromideCapsule, extended release8 mg/1OralPatriot Pharmaceuticals, LLC2004-12-22Not applicableUs
Galantamine HydrobromideTablet, film coated8 mg/1OralYabao Pharmaceutical Co., Ltd. Beijing2001-03-01Not applicableUs
Galantamine HydrobromideTablet, film coated4 mg/1OralPatriot Pharmaceuticals, LLC2001-02-28Not applicableUs
Ipg-galantamine ERCapsule, extended release16 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-galantamine ERCapsule, extended release8 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-galantamine ERCapsule, extended release24 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-galantamine ERCapsule, extended release24 mgOralMarcan Pharmaceuticals Inc2015-03-25Not applicableCanada
Mar-galantamine ERCapsule, extended release8 mgOralMarcan Pharmaceuticals Inc2015-02-25Not applicableCanada
Mar-galantamine ERCapsule, extended release16 mgOralMarcan Pharmaceuticals Inc2015-02-25Not applicableCanada
Mylan-galantamine ERCapsule, extended release8 mgOralMylan Pharmaceuticals Ulc2010-11-12Not applicableCanada
Mylan-galantamine ERCapsule, extended release16 mgOralMylan Pharmaceuticals Ulc2010-11-12Not applicableCanada
Mylan-galantamine ERCapsule, extended release24 mgOralMylan Pharmaceuticals Ulc2010-11-12Not applicableCanada
Pat-galantamine ERCapsule, extended release24 mgOralPatriot A Division Of Janssen Inc2011-01-05Not applicableCanada
Pat-galantamine ERCapsule, extended release8 mgOralPatriot A Division Of Janssen Inc2011-01-05Not applicableCanada
Pat-galantamine ERCapsule, extended release16 mgOralPatriot A Division Of Janssen Inc2011-01-05Not applicableCanada
Pendo-galantamine ERCapsule, extended release8 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-galantamineTablet4 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-galantamineTablet8 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-galantamineTablet12 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-galantamine ERCapsule, extended release16 mgOralPharmascience Inc2013-06-13Not applicableCanada
PMS-galantamine ERCapsule, extended release24 mgOralPharmascience Inc2013-06-13Not applicableCanada
PMS-galantamine ERCapsule, extended release8 mgOralPharmascience Inc2013-06-13Not applicableCanada
Ratio-galantamineTablet4 mgOralRatiopharm Inc Division Of Teva Canada LimitedNot applicableNot applicableCanada
Ratio-galantamineTablet8 mgOralRatiopharm Inc Division Of Teva Canada LimitedNot applicableNot applicableCanada
Ratio-galantamineTablet12 mgOralRatiopharm Inc Division Of Teva Canada LimitedNot applicableNot applicableCanada
RazadyneTablet, film coated8 mg/1OralRebel Distributors Corp2001-02-28Not applicableUs
RazadyneSolution4 mg/mLOralJanssen Pharmaceuticals, Inc.2001-06-22Not applicableUs
RazadyneCapsule, extended release24 mg/1OralJanssen Pharmaceuticals, Inc.2004-12-24Not applicableUs
RazadyneTablet, film coated12 mg/1OralRebel Distributors Corp2001-02-28Not applicableUs
RazadyneTablet, film coated4 mg/1OralJanssen Pharmaceuticals, Inc.2001-03-01Not applicableUs
RazadyneCapsule, extended release8 mg/1OralJanssen Pharmaceuticals, Inc.2004-12-24Not applicableUs
RazadyneTablet, film coated8 mg/1OralJanssen Pharmaceuticals, Inc.2001-03-01Not applicableUs
RazadyneCapsule, extended release16 mg/1OralJanssen Pharmaceuticals, Inc.2004-12-24Not applicableUs
RazadyneTablet, film coated12 mg/1OralJanssen Pharmaceuticals, Inc.2001-03-01Not applicableUs
Reminyl -(12mg)Tablet12 mgOralJanssen Inc2001-08-102009-08-05Canada
Reminyl -(4mg)Tablet4 mgOralJanssen Inc2001-08-082009-08-05Canada
Reminyl -(8mg)Tablet8 mgOralJanssen Inc2001-08-082009-08-05Canada
Reminyl ERCapsule, extended release16 mgOralJanssen Inc2005-04-29Not applicableCanada
Reminyl ERCapsule, extended release24 mgOralJanssen Inc2005-04-29Not applicableCanada
Reminyl ERCapsule, extended release8 mgOralJanssen Inc2005-04-29Not applicableCanada
Sandoz Galantamine ERCapsule, extended release16 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Galantamine ERCapsule, extended release24 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Galantamine ERCapsule, extended release8 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Teva-galantamine ERCapsule, extended release8 mgOralTeva Canada Limited2012-01-06Not applicableCanada
Teva-galantamine ERCapsule, extended release16 mgOralTeva Canada Limited2012-01-06Not applicableCanada
Teva-galantamine ERCapsule, extended release24 mgOralTeva Canada Limited2012-01-06Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-galantamineTablet8 mgOralApotex IncNot applicableNot applicableCanada
Apo-galantamineTablet12 mgOralApotex IncNot applicableNot applicableCanada
Apo-galantamineTablet4 mgOralApotex IncNot applicableNot applicableCanada
GalantamineTablet, film coated4 mg/1OralApotex Corp.2012-11-05Not applicableUs
GalantamineTablet, film coated4 mg/1OralBarr Laboratories Inc.2008-08-28Not applicableUs
GalantamineTablet, film coated12 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralAurobindo Pharma Limited2011-03-29Not applicableUs
GalantamineTablet, film coated12 mg/1OralMylan Pharmaceuticals Inc.2008-08-29Not applicableUs
GalantamineCapsule, extended release24 mg/1OralBarr Laboratories Inc.2008-10-15Not applicableUs
GalantamineTablet, film coated4 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-03-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralMylan Institutional Inc.2009-11-09Not applicableUs
GalantamineTablet, film coated8 mg/1OralZydus Pharmaceuticals (USA) Inc.2011-10-10Not applicableUs
GalantamineTablet4 mg/1OralWest Ward Pharmaceuticals Corp.2016-06-01Not applicableUs
GalantamineTablet, film coated8 mg/1OralApotex Corp.2012-11-05Not applicableUs
GalantamineTablet, film coated8 mg/1OralBarr Laboratories Inc.2008-08-28Not applicableUs
GalantamineCapsule, extended release8 mg/1OralAurobindo Pharma Limited2016-08-05Not applicableUs
GalantamineTablet, film coated8 mg/1OralAurobindo Pharma Limited2011-03-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralCitron Pharma LLC2011-03-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralCadila Healthcare Limited2011-10-10Not applicableUs
GalantamineTablet, film coated4 mg/1OralAmerican Health Packaging2014-06-23Not applicableUs
GalantamineTablet, film coated8 mg/1OralMylan Institutional Inc.2009-11-09Not applicableUs
GalantamineTablet, film coated12 mg/1OralZydus Pharmaceuticals (USA) Inc.2011-10-10Not applicableUs
GalantamineTablet8 mg/1OralWest Ward Pharmaceuticals Corp.2016-06-01Not applicableUs
GalantamineTablet, film coated12 mg/1OralApotex Corp.2012-11-05Not applicableUs
GalantamineCapsule, extended release8 mg/1OralBarr Laboratories Inc.2008-10-14Not applicableUs
GalantamineTablet, film coated12 mg/1OralBarr Laboratories Inc.2008-08-28Not applicableUs
GalantamineCapsule, extended release16 mg/1OralAurobindo Pharma Limited2016-08-05Not applicableUs
GalantamineTablet, film coated12 mg/1OralAurobindo Pharma Limited2011-03-29Not applicableUs
GalantamineTablet, film coated8 mg/1OralCitron Pharma LLC2011-03-29Not applicableUs
GalantamineTablet, film coated8 mg/1OralCadila Healthcare Limited2011-10-10Not applicableUs
GalantamineTablet, film coated4 mg/1OralMylan Pharmaceuticals Inc.2008-08-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not applicableUs
GalantamineTablet, film coated12 mg/1OralMylan Institutional Inc.2009-11-09Not applicableUs
GalantamineTablet12 mg/1OralWest Ward Pharmaceuticals Corp.2016-06-01Not applicableUs
GalantamineTablet, film coated8 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-03-29Not applicableUs
GalantamineCapsule, extended release16 mg/1OralBarr Laboratories Inc.2008-10-15Not applicableUs
GalantamineCapsule, extended release24 mg/1OralAurobindo Pharma Limited2016-08-05Not applicableUs
GalantamineTablet, film coated12 mg/1OralCitron Pharma LLC2011-03-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralZydus Pharmaceuticals (USA) Inc.2011-10-10Not applicableUs
GalantamineTablet, film coated12 mg/1OralCadila Healthcare Limited2011-10-10Not applicableUs
GalantamineTablet, film coated8 mg/1OralMylan Pharmaceuticals Inc.2008-08-29Not applicableUs
GalantamineTablet, film coated8 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not applicableUs
Galantamine HydrobromideCapsule, extended release16 mg/1OralAphena Pharma Solutions Tennessee, Llc2009-12-15Not applicableUs
Galantamine HydrobromideSolution4 mg/mLOralRoxane Laboratories, Inc2009-08-14Not applicableUs
Galantamine HydrobromideCapsule, extended release16 mg/1OralWatson Laboratories, Inc.2009-12-15Not applicableUs
Galantamine HydrobromideCapsule, extended release8 mg/1OralMylan Pharmaceuticals Inc.2011-01-24Not applicableUs
Galantamine HydrobromideCapsule, extended release8 mg/1OralSun Pharma Global FZE2011-02-09Not applicableUs
Galantamine HydrobromideCapsule, extended release8 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not applicableUs
Galantamine HydrobromideCapsule, extended release24 mg/1OralWatson Laboratories, Inc.2009-12-15Not applicableUs
Galantamine HydrobromideCapsule, extended release16 mg/1OralMylan Pharmaceuticals Inc.2011-01-24Not applicableUs
Galantamine HydrobromideCapsule, extended release16 mg/1OralSun Pharma Global FZE2011-02-09Not applicableUs
Galantamine HydrobromideCapsule, extended release16 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not applicableUs
Galantamine HydrobromideCapsule, extended release24 mg/1OralMylan Pharmaceuticals Inc.2011-01-24Not applicableUs
Galantamine HydrobromideCapsule, extended release8 mg/1OralWatson Laboratories, Inc.2009-12-15Not applicableUs
Galantamine HydrobromideCapsule, extended release24 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not applicableUs
Galantamine HydrobromideCapsule, extended release24 mg/1OralSun Pharma Global FZE2011-02-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LycoremineNot Available
NivalinNot Available
ReminylNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Galantamine hydrobromide
1953-04-4
Thumb
  • InChI Key: QORVDGQLPPAFRS-XPSHAMGMSA-N
  • Monoisotopic Mass: 367.078306222
  • Average Mass: 368.265
DBSALT000316
Categories
UNII0D3Q044KCA
CAS number357-70-0
WeightAverage: 287.3535
Monoisotopic: 287.152143543
Chemical FormulaC17H21NO3
InChI KeyASUTZQLVASHGKV-JDFRZJQESA-N
InChI
InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
IUPAC Name
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
SMILES
[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Pharmacology
IndicationFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
Structured Indications
PharmacodynamicsGalantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.
Mechanism of actionGalantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
AcetylcholinesteraseProteinyes
inhibitor
HumanP22303 details
Acetylcholine receptor subunit alphaProteinunknown
allosteric modulator
HumanP02708 details
Acetylcholine receptor subunit betaProteinunknown
allosteric modulator
HumanP11230 details
Acetylcholine receptor subunit deltaProteinunknown
allosteric modulator
HumanQ07001 details
Acetylcholine receptor subunit gammaProteinunknown
allosteric modulator
HumanP07510 details
Acetylcholine receptor subunit epsilonProteinunknown
allosteric modulator
HumanQ04844 details
Neuronal acetylcholine receptor subunit alpha-2Proteinunknown
allosteric modulator
HumanQ15822 details
Neuronal acetylcholine receptor subunit alpha-3Proteinunknown
allosteric modulator
HumanP32297 details
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
allosteric modulator
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-5Proteinunknown
allosteric modulator
HumanP30532 details
Neuronal acetylcholine receptor subunit alpha-6Proteinunknown
allosteric modulator
HumanQ15825 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
allosteric modulator
HumanP36544 details
Neuronal acetylcholine receptor subunit alpha-9Proteinunknown
allosteric modulator
HumanQ9UGM1 details
Neuronal acetylcholine receptor subunit alpha-10Proteinunknown
allosteric modulator
HumanQ9GZZ6 details
Neuronal acetylcholine receptor subunit beta-2Proteinunknown
allosteric modulator
HumanP17787 details
Neuronal acetylcholine receptor subunit beta-3Proteinunknown
allosteric modulator
HumanQ05901 details
Neuronal acetylcholine receptor subunit beta-4Proteinunknown
allosteric modulator
HumanP30926 details
CholinesteraseProteinunknown
inhibitor
HumanP06276 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 175 L
Protein binding18%
MetabolismNot Available
Route of eliminationGalantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine.
Half life7 hours
Clearance
  • 300 mL/min [After IV. or oral administration]
ToxicityLD50=75 mg/kg (rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Galantamine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Galantamine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Galantamine.Experimental, Illicit
AbirateroneThe serum concentration of Galantamine can be increased when it is combined with Abiraterone.Approved
AcebutololGalantamine may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Galantamine is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Galantamine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Galantamine.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Galantamine.Experimental
AlprenololGalantamine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Galantamine.Approved
AmiodaroneThe metabolism of Galantamine can be decreased when combined with Amiodarone.Approved, Investigational
AnagrelideGalantamine may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Galantamine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Galantamine.Approved
Aop200704Galantamine may increase the bradycardic activities of Aop200704.Investigational
AprepitantThe serum concentration of Galantamine can be increased when it is combined with Aprepitant.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Galantamine is combined with Arecoline.Experimental
ArotinololGalantamine may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideGalantamine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherGalantamine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineGalantamine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Galantamine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololGalantamine may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe metabolism of Galantamine can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Galantamine.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Galantamine.Approved, Vet Approved
AzithromycinGalantamine may increase the QTc-prolonging activities of Azithromycin.Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Galantamine.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Galantamine.Approved, Investigational
BedaquilineGalantamine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololGalantamine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Galantamine.Withdrawn
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Galantamine.Approved
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Galantamine.Approved
BeractantGalantamine may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Galantamine.Approved, Vet Approved
BetaxololGalantamine may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Galantamine is combined with Bethanechol.Approved
BevantololGalantamine may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe serum concentration of Galantamine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Galantamine.Approved
BisoprololGalantamine may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe metabolism of Galantamine can be decreased when combined with Boceprevir.Approved
BopindololGalantamine may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe metabolism of Galantamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Galantamine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Galantamine.Approved
BucindololGalantamine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Galantamine.Approved
BufuralolGalantamine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololGalantamine may increase the bradycardic activities of Bupranolol.Approved
BupropionThe metabolism of Galantamine can be decreased when combined with Bupropion.Approved
CalfactantGalantamine may increase the bradycardic activities of Calfactant.Approved
CarbacholThe risk or severity of adverse effects can be increased when Galantamine is combined with Carbachol.Approved
CarbamazepineThe metabolism of Galantamine can be increased when combined with Carbamazepine.Approved, Investigational
CarteololGalantamine may increase the bradycardic activities of Carteolol.Approved
CarvedilolGalantamine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Galantamine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololGalantamine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibGalantamine may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Galantamine is combined with Cevimeline.Approved
ChloroquineGalantamine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Galantamine.Withdrawn
ChlorpromazineGalantamine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Galantamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Galantamine.Approved, Investigational
CimetidineThe metabolism of Galantamine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Galantamine can be decreased when combined with Cinacalcet.Approved
CiprofloxacinGalantamine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideGalantamine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Galantamine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Galantamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Galantamine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Galantamine can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Galantamine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Galantamine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine.Approved
ClomipramineThe metabolism of Galantamine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the bradycardic activities of Galantamine.Approved
ClotrimazoleThe metabolism of Galantamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineGalantamine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Galantamine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Galantamine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Galantamine can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Galantamine.Approved
CrizotinibGalantamine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Galantamine.Approved
CyclosporineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.Approved
DapoxetineThe metabolism of Galantamine can be decreased when combined with Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine.Approved, Investigational
DarunavirThe serum concentration of Galantamine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Galantamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Galantamine can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Galantamine.Investigational
DelavirdineThe metabolism of Galantamine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Galantamine can be decreased when combined with Desipramine.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Galantamine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Galantamine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Galantamine.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Galantamine can be decreased when combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Galantamine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Galantamine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Galantamine.Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Galantamine.Approved, Vet Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Galantamine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Galantamine.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Galantamine.Approved
DigoxinDigoxin may increase the bradycardic activities of Galantamine.Approved
DihydroergotamineThe metabolism of Galantamine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Galantamine can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Galantamine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.Approved
DisopyramideGalantamine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideGalantamine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronGalantamine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneGalantamine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilGalantamine may increase the bradycardic activities of Donepezil.Approved
DoxycyclineThe metabolism of Galantamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneGalantamine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolGalantamine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineThe metabolism of Galantamine can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Galantamine can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatGalantamine may increase the QTc-prolonging activities of Eliglustat.Approved
EnzalutamideThe serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Galantamine is combined with EPIBATIDINE.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Galantamine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Galantamine.Approved
ErythromycinGalantamine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Galantamine can be decreased when combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Galantamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololGalantamine may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Galantamine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Galantamine.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Galantamine.Approved
EtoperidoneThe metabolism of Galantamine can be decreased when combined with Etoperidone.Approved
EtravirineThe serum concentration of Galantamine can be decreased when it is combined with Etravirine.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.Approved
FingolimodGalantamine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideGalantamine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Galantamine.Investigational
FluconazoleThe metabolism of Galantamine can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Galantamine.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Galantamine.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Galantamine.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Galantamine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Galantamine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Galantamine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Galantamine.Approved
FluoxetineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolGalantamine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Galantamine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Galantamine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Galantamine.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Galantamine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Galantamine.Approved
FluvoxamineThe metabolism of Galantamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Galantamine.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Galantamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Galantamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Galantamine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Galantamine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGalantamine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Galantamine.Approved
GemifloxacinGalantamine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Galantamine.Approved, Investigational, Vet Approved
GoserelinGalantamine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronGalantamine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Galantamine is combined with GTS-21.Investigational
GuanfacineGalantamine may increase the bradycardic activities of Guanfacine.Approved, Investigational
HaloperidolGalantamine may increase the QTc-prolonging activities of Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Galantamine.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Galantamine.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Galantamine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Galantamine.Approved
IbutilideGalantamine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Galantamine can be increased when it is combined with Idelalisib.Approved
IloperidoneGalantamine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Galantamine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Galantamine can be decreased when combined with Imipramine.Approved
IndalpineThe metabolism of Galantamine can be decreased when combined with Indalpine.Investigational, Withdrawn
IndenololGalantamine may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Galantamine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.Approved
IsavuconazoniumThe metabolism of Galantamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Galantamine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Galantamine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Galantamine.Investigational
ItraconazoleThe metabolism of Galantamine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineGalantamine may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Galantamine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Galantamine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolGalantamine may increase the bradycardic activities of Labetalol.Approved
LacosamideGalantamine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideGalantamine may increase the bradycardic activities of Lanreotide.Approved
LenvatinibGalantamine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideGalantamine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololGalantamine may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinGalantamine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe metabolism of Galantamine can be decreased when combined with Levomilnacipran.Approved
LobelineThe risk or severity of adverse effects can be increased when Galantamine is combined with Lobeline.Investigational
LopinavirThe metabolism of Galantamine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Galantamine can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Galantamine can be decreased when combined with Lovastatin.Approved, Investigational
LucinactantGalantamine may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Galantamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Galantamine can be increased when combined with Lumacaftor.Approved
LumefantrineGalantamine may increase the QTc-prolonging activities of Lumefantrine.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Galantamine.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Galantamine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Galantamine.Vet Approved
MethacholineThe risk or severity of adverse effects can be increased when Galantamine is combined with Methacholine.Approved
MethadoneGalantamine may increase the QTc-prolonging activities of Methadone.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Galantamine.Approved
MethotrimeprazineThe metabolism of Galantamine can be decreased when combined with Methotrimeprazine.Approved
MethyldopaGalantamine may increase the bradycardic activities of Methyldopa.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine.Approved, Vet Approved
MetipranololGalantamine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Galantamine.Approved
MetoprololGalantamine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Galantamine.Approved, Investigational
MilnacipranThe metabolism of Galantamine can be decreased when combined with Milnacipran.Approved
MirabegronThe metabolism of Galantamine can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Galantamine can be decreased when it is combined with Mitotane.Approved
MivacuriumGalantamine may decrease the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Galantamine can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Galantamine.Approved, Vet Approved
MoxifloxacinGalantamine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Galantamine.Vet Approved
NadololGalantamine may increase the bradycardic activities of Nadolol.Approved
NafcillinThe serum concentration of Galantamine can be decreased when it is combined with Nafcillin.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Galantamine.Investigational
NebivololGalantamine may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Galantamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Galantamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Galantamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Galantamine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Galantamine can be decreased when combined with Nicardipine.Approved
NicotineThe risk or severity of adverse effects can be increased when Galantamine is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Galantamine is combined with Nicotine bitartrate.Approved
NilotinibGalantamine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Galantamine.Investigational
OctreotideOctreotide may increase the bradycardic activities of Galantamine.Approved, Investigational
OfloxacinGalantamine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Galantamine can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Galantamine.Investigational
OndansetronGalantamine may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Galantamine.Approved
OsimertinibThe serum concentration of Galantamine can be increased when it is combined with Osimertinib.Approved
OxprenololGalantamine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Galantamine.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Galantamine.Approved
PalbociclibThe serum concentration of Galantamine can be increased when it is combined with Palbociclib.Approved
PaliperidoneGalantamine may increase the QTc-prolonging activities of Paliperidone.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.Approved
PanobinostatThe serum concentration of Galantamine can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Galantamine.Approved
ParoxetineThe metabolism of Galantamine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideGalantamine may increase the bradycardic activities of Pasireotide.Approved
PazopanibGalantamine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololGalantamine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineGalantamine may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Galantamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Galantamine.Approved
PerflutrenGalantamine may increase the QTc-prolonging activities of Perflutren.Approved
PhenobarbitalThe metabolism of Galantamine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Galantamine can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe risk or severity of adverse effects can be increased when Galantamine is combined with Pilocarpine.Approved
PimozideGalantamine may increase the QTc-prolonging activities of Pimozide.Approved
PindololGalantamine may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.Approved
Poractant alfaGalantamine may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Galantamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololGalantamine may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Galantamine.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Galantamine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Galantamine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Galantamine.Experimental
PrimaquineGalantamine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Galantamine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideGalantamine may increase the QTc-prolonging activities of Procainamide.Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Galantamine.Approved
PromazineGalantamine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneGalantamine may increase the QTc-prolonging activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Galantamine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Galantamine.Investigational
PropranololGalantamine may increase the bradycardic activities of Propranolol.Approved, Investigational
QuetiapineGalantamine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineGalantamine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineGalantamine may increase the QTc-prolonging activities of Quinine.Approved
RanolazineThe metabolism of Galantamine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumGalantamine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RifabutinThe metabolism of Galantamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Galantamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Galantamine can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Galantamine.Approved
RitonavirThe metabolism of Galantamine can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineGalantamine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Galantamine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Galantamine can be decreased when combined with Ropinirole.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Galantamine.Approved
SaquinavirThe metabolism of Galantamine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Galantamine.Approved
SertralineThe metabolism of Galantamine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Galantamine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Galantamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Galantamine can be increased when it is combined with Simeprevir.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Galantamine.Approved
SotalolGalantamine may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Galantamine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Galantamine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Galantamine.Approved
SufentanilGalantamine may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfisoxazoleGalantamine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Galantamine can be decreased when combined with Telaprevir.Approved
TelavancinGalantamine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Galantamine can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Galantamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineGalantamine may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineGalantamine may increase the QTc-prolonging activities of Thioridazine.Approved
TiclopidineThe metabolism of Galantamine can be decreased when combined with Ticlopidine.Approved
TimololGalantamine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Galantamine.Approved
TipranavirThe metabolism of Galantamine can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Galantamine.Approved
TizanidineGalantamine may increase the bradycardic activities of Tizanidine.Approved
TocilizumabThe serum concentration of Galantamine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Galantamine.Approved, Investigational
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Galantamine.Approved, Investigational
ToremifeneGalantamine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranylcypromineThe metabolism of Galantamine can be decreased when combined with Tranylcypromine.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Galantamine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Galantamine.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Galantamine.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Galantamine.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Galantamine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Galantamine.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Galantamine.Approved
VandetanibGalantamine may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe risk or severity of adverse effects can be increased when Galantamine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.Approved
VemurafenibGalantamine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Galantamine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Galantamine can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Galantamine can be decreased when combined with Voriconazole.Approved, Investigational
ZimelidineThe metabolism of Galantamine can be decreased when combined with Zimelidine.Withdrawn
ZiprasidoneGalantamine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolGalantamine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food.
References
Synthesis Reference

Vijaya Bolugoddu, Sanjay Shukla, Mukunda Jambula, Rajeshwar Sagyam, Ramchandra Pingili, Ananda Thirunavakarasu, “Preparation of (-)-galantamine hydrobromide.” U.S. Patent US20060009640, issued January 12, 2006.

US20060009640
General References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746 ]
  3. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. [PubMed:11172080 ]
  4. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. [PubMed:16437532 ]
  5. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  6. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
External Links
ATC CodesN06DA04
AHFS Codes
  • 12:04.00
PDB EntriesNot Available
FDA labelDownload (278 KB)
MSDSDownload (28.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9959
Caco-2 permeable+0.8259
P-glycoprotein substrateSubstrate0.8976
P-glycoprotein inhibitor IInhibitor0.6069
P-glycoprotein inhibitor IINon-inhibitor0.9443
Renal organic cation transporterInhibitor0.5728
CYP450 2C9 substrateNon-substrate0.8072
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.5414
CYP450 2C19 inhibitorNon-inhibitor0.8301
CYP450 3A4 inhibitorNon-inhibitor0.8832
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9439
Ames testNon AMES toxic0.7995
CarcinogenicityNon-carcinogens0.9055
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7790 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8023
hERG inhibition (predictor II)Non-inhibitor0.7424
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Impax laboratories inc
  • Watson laboratories inc
  • Ortho mcneil janssen pharmaceuticals inc
  • Roxane laboratories inc
  • Ortho mcneil janssen pharmaceutical inc
  • Actavis elizabeth llc
  • Beijing yabao biopharmaceutical co ltd
  • Dr reddys laboratories ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
TabletOral12 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
Tablet, film coatedOral12 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral8 mg/1
Capsule, extended releaseOral16 mg/1
Capsule, extended releaseOral24 mg/1
Capsule, extended releaseOral8 mg/1
SolutionOral4 mg/mL
TabletOral12 mg
TabletOral4 mg
TabletOral8 mg
Capsule, extended releaseOral16 mg
Capsule, extended releaseOral24 mg
Capsule, extended releaseOral8 mg
Prices
Unit descriptionCostUnit
Galantamine Hydrobromide 30 16 mg 24 Hour Capsule Bottle198.58USD bottle
Galantamine Hydrobromide 30 8 mg 24 Hour Capsule Bottle198.58USD bottle
Razadyne 12 mg tablet8.3USD tablet
Razadyne 4 mg tablet5.36USD tablet
Razadyne 8 mg tablet3.66USD tablet
Galantamine hbr 12 mg tablet3.18USD tablet
Galantamine hbr 4 mg tablet3.18USD tablet
Galantamine hbr 8 mg tablet3.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2310926 No2001-11-202017-06-06Canada
CA2358062 No2006-12-192019-12-20Canada
US6099863 No1997-06-062017-06-06Us
US6358527 No1997-06-062017-06-06Us
US7160559 No1999-12-202019-12-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point269-270 °C (HBr salt)Not Available
water solubility10 mg/mL (HBr salt)Not Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.7 mg/mLALOGPS
logP1.39ALOGPS
logP1.16ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)14.81ChemAxon
pKa (Strongest Basic)8.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.3 m3·mol-1ChemAxon
Polarizability31.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000l-5980000000-928ad889466b6a2b3827View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as galanthamine-type amaryllidaceae alkaloids. These are amaryllidaceae alkaloids with a structure characterized a tetracyclic skeleton with two ortho aromatic protons in ring A.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassAmaryllidaceae alkaloids
Sub ClassGalanthamine-type amaryllidaceae alkaloids
Direct ParentGalanthamine-type amaryllidaceae alkaloids
Alternative Parents
Substituents
  • Galanthamine-type amaryllidaceae alkaloid
  • Benzazepine
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Azepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Tonkopii VD, Prozorovskii VB, Suslova IM: [Interaction of reversible inhibitors with the catalytic centers and allosteric sites of cholinesterases]. Biull Eksp Biol Med. 1976 Aug;82(8):947-50. [PubMed:1026294 ]
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746 ]
  3. Guillou C, Mary A, Renko DZ, Gras E, Thal C: Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett. 2000 Apr 3;10(7):637-9. [PubMed:10762042 ]
  4. Blesa R: Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:28-34. [PubMed:10971049 ]
  5. Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1. [PubMed:11078030 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  8. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  9. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  10. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  11. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  12. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
  13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA1
Uniprot ID:
P02708
Molecular Weight:
54545.235 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB1
Uniprot ID:
P11230
Molecular Weight:
56697.9 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Acetylcholine-activated cation-selective channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRND
Uniprot ID:
Q07001
Molecular Weight:
58894.55 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNG
Uniprot ID:
P07510
Molecular Weight:
57882.8 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Cation transmembrane transporter activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNE
Uniprot ID:
Q04844
Molecular Weight:
54696.54 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA3
Uniprot ID:
P32297
Molecular Weight:
57479.54 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA5
Uniprot ID:
P30532
Molecular Weight:
53053.965 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Acetylcholine-activated cation-selective channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA6
Uniprot ID:
Q15825
Molecular Weight:
56897.745 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Calcium channel activity
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the ...
Gene Name:
CHRNA9
Uniprot ID:
Q9UGM1
Molecular Weight:
54806.63 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.
Gene Name:
CHRNB2
Uniprot ID:
P17787
Molecular Weight:
57018.575 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB3
Uniprot ID:
Q05901
Molecular Weight:
52728.215 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB4
Uniprot ID:
P30926
Molecular Weight:
56378.985 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686 ]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048 ]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195 ]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . 2006 Jun;():. [PubMed:20480924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Svoboda Z, Kvetina J, Kunesova G, Herink J, Bajgar J, Bartosova L, Zivny P, Palicka V: Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:183-6. [PubMed:17159811 ]
  2. Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8. [PubMed:11888344 ]
  3. Wilkinson DG: Galantamine: a new treatment for Alzheimer's disease. Expert Rev Neurother. 2001 Nov;1(2):153-9. doi: 10.1586/14737175.1.2.153. [PubMed:19811027 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:38